Survival Data

For the 10th Consecutive Year, NSH BMT Program’s Survival Outcomes Among the Nation’s Best

 

For the 10th consecutive year, The Blood and Marrow Transplant (BMT) Program at Northside Hospital Cancer Institute has been recognized as having among the best survival outcomes in the United States for bone marrow transplants. The data was reported by Be The Match®, which manages the largest and most diverse marrow registry in the world. Please click here to view 2018 Survival brochure.

Northside ranks in the top 20 percent of transplant programs in the country in terms of volume of allogeneic transplants performed. According to the data, the one-year survival rate of transplant patients at Northside is 79.4 percent, which exceeds the survival expected for the hospital.

The hospital’s BMT Program is one of only two adult programs in the nation (out of 177) that has achieved survival outcomes that significantly exceeded the expected survival rate for the last 10 consecutive reporting cycles. It is the longest running adult program in the Southeast to exceed expected survival rates.

Kent Holland, M.D., medical director of The BMT Program at Northside Hospital Cancer Institute, believes that these results are a direct reflection of the hard-working dedication of Northside’s physicians and staff. “We have a very experienced team that spearheads the amazing work that takes place in our inpatient and outpatient BMT units, our stem-cell laboratory and blood donor center,” he said.

In addition to state-of-the-art facilities and expert leadership, innovative treatments and research are major components of the BMT Program at Northside. Northside recently began offering chimeric antigen receptor (CAR) T-cell therapy and other immunotherapy treatment options including novel clinical research trials. It is the lead site for a consortium with the Blood and Marrow Transplant Clinical Trials Network (BMTCTN), which conducts large multi-institutional clinical trials that address important issues in hematopoietic stem cell transplantation and furthers the understanding of the best possible treatment approaches.

“At Northside, we are committed to providing our patients with outstanding clinical care as demonstrated by our patient-centered, comprehensive quality management program,” said Dr. Holland.

For more information about the Blood and Marrow Transplant Program at Northside Hospital Cancer Institute, visit www.builttobeatcancer.com and www.BMTGA.com. For more information about Be The Match, visit www.BeTheMatch.org.